Tanabe Pharma Corporation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Mitsubishi Tanabe Pharma Corporation (to 2026)
6
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 6 to 25, 2026 · next Dec 6
- 1 fee due Feb 28, 2027The maintenance fee for Analysis Method of 3-Methyl-1-Phenyl-2-Pyrazolin-5-ONE Active Pharmaceutical Ingredient, Treatment for Amyotrophic Lateral Sclerosis, Inhibition of Progression of Amyotrophic Lateral Sclerosis, and Method of Producing Medicament Containing 3-Methyl-1-Phenyl-2-Pyrazolin-5-ONE Active Pharmaceutical Ingredient (US 11,740,219) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Compounds and Their Use (US 11,970,463) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,788 | Glucopyranoside Compound In force · High confidence | In force | High confidence | |
| US 8,513,202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate In force · From the USPTO record | In force | From the USPTO record | |
| US 8,198,287 | Substituted Heteroaryl Pyridopyrimidone Derivatives In force · High confidence | In force | High confidence | |
| US 9,956,203 | Plastic container comprising cyclic polyolefin layer In force · From the USPTO record | In force | From the USPTO record | |
| US 7,943,582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate In force · From the USPTO record | In force | From the USPTO record | |
| US 8,809,304 | Amine compound and use thereof for medical purposes In force · From the USPTO record | In force | From the USPTO record | |
| US 9,655,852 | Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound In force · From the USPTO record | In force | From the USPTO record | |
| US 9,024,009 | Process for the Preparation of Compounds Useful as Inhibitors of SGLT In force · High confidence | In force | High confidence | |
| US 10,004,720 | Agent for preventing and/or treating ophthalmologic diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,065,972 | Bicyclic or tricyclic heterocyclic compound In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 34: 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.